Description
General description
PURedit® Cas9 Precision Cytosine Base Editor has been engineered to achieve defined nucleotide changes of cytosine to thymine using RNP complex delivery. The PURedit® Cas9 Precision Cytosine Base Editor will edit cytosine residues from the third position of the protospacer to the ninth position. The base editor protein is recombinantly expressed in E. coli with 2X NLS. Uracil glycosylase inhibitor (UGI) protein, also recombinantly expressed in E. coli with 2X NLS, is included as a recommended optional component to enhance the rate of C-to-T editing and reduce the rate of other editing outcomes, including insertions and deletions (indels). UGI may be omitted to enable lower-frequency C-to-R (R = A or G) editing..
The kit contains:
Cytosine Base Editor protein (CAS9CBEPRC) in 50% glycerol at 8 mg/mL
Uracil glycosylase inhibitor (UGIPRT) in 50% glycerol at 15 mg/mL
Transfection buffer (PEXBUF)
Dilution buffer (DBUFFER)
For best performance, gRNA sequence should be designed using our free online DNA base editor tool. Link here: SigmaAldrich.com/baseeditordesign
We also recommend our gRNA products for use with the PURedit® Cas9 Cytosine Base Editor kits. Order your custom gRNA here: SigmaAldrich.com/customgrna
Application
Genome editing
Functional genomics
CRISPR screening
Cell culture
Embryos
Features and Benefits
Best in class protein offering of cytosine base editors. Safer gene editing without double stranded breaks allows for editing in sensitive cell lines and eliminates the risk of nonspecific donor DNA integration.
Precision Editing: high rates of C-to-T substitution at only the target site; reduced risks of off-target edits relative to plasmid or viral delivery.
Resource savings: screen fewer clones due to more predictable editing.
Legal Information
CRISPR Use License Agreement: https://www.sigmaaldrich.com/US/en/life-science/legal/product-licenses/crispr-use-license-agreement
PURedit is a registered trademark of Merck KGaA, Darmstadt, Germany
